You can buy or sell Novavax and other stocks, options, and ETFs commission-free!
Novavax, Inc. Common Stock, also called Novavax, is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD. The listed name for NVAX is Novavax, Inc. Common Stock.
Stanley C. Erck
52 Week High
52 Week Low
Novavax Inc. stock rises Friday, outperforms market
Shares of Novavax Inc. NVAX, +10.59% jumped 10.59% to $174.84 Friday, on what proved to be an all-around great trading session for the stock market, with the NA
Yahoo FinanceMar 1
Novavax CEO on COVID-19 vaccine trial progress
Novavax CEO Stanley Erck joined Yahoo Finance Live to discuss the company's COVID-19 vaccine trial progress and his business outlook for the company. Video Tra
-$1.49 per share
-$2.70 per share